Aveo's cancer drug circles the drain after a scuttled Phase II trial

Aveo Oncology ($AVEO) and Astellas Pharma are shutting down a Phase II study of tivozanib in breast cancer after failing to enroll enough patients, the partners announced. Last month, the two pulled the plug on a separate Phase II study in patients with colorectal cancer after an interim analysis revealed that the VEGF inhibitor was unlikely to meet its primary endpoint. Last summer, the FDA resoundingly rejected a kidney cancer application for the drug, calling its Phase III data "uninterpretable." The latest setback could well spell the end for tivozanib, which appears to be fresh out of potential indications. More

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.